MONTREAL, QUEBEC--(MARKET WIRE)--Jul 20, 2007 -- Mistral Pharma Inc. (CDNX:MIP.V - News)(“Mistral”) announced today results from a first pilot pharmacokinetic (PK) study on its MIST-B03 product. The results of this pilot study show that MIST-B03, which is designed using the CHRONOP(TM) technology, presents the expected pulse release profile for both active ingredients that are included in the formulation.
